LG-121071

LG-121071 is a synthetic androgen and anabolic steroid and a selective androgen receptor modulator (SARM) that was developed by Ligand Pharmaceuticals. It has been investigated for potential medical applications such as the treatment of osteoporosis and muscle wasting diseases.

History

LG-121071 was first synthesized by Ligand Pharmaceuticals, a biopharmaceutical company based in San Diego, California. The company specializes in the development of drugs that target nuclear receptors, including the androgen receptor.

Pharmacology

As a SARM, LG-121071 selectively binds to the androgen receptor, which is a type of nuclear receptor that is activated by binding any of the androgenic hormones, including testosterone and dihydrotestosterone. By selectively binding to the androgen receptor, LG-121071 is able to stimulate anabolic activity in muscles and bones while minimizing the androgenic effects in other tissues.

Clinical Trials

LG-121071 has undergone clinical trials to evaluate its safety and efficacy in the treatment of conditions such as osteoporosis and muscle wasting diseases. However, as of now, it has not been approved for medical use.

Potential Applications

The potential applications of LG-121071 are primarily in the field of medicine. It could potentially be used to treat conditions such as osteoporosis, muscle wasting diseases, and perhaps even cancer-related cachexia. However, further research and clinical trials are needed to fully understand its potential benefits and risks.

See Also

• Selective androgen receptor modulator
• Androgen receptor
• Ligand Pharmaceuticals
• Osteoporosis
• Muscle wasting